J. Cosin-aguilar et al., Long-term results of the Spanish trial on treatment and survival of patients with predominantly mild heart failure, J CARDIO PH, 33(5), 1999, pp. 733-740
Citations number
32
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
A randomized open-label clinical trial was conducted to determine whether m
ortality, readmission, or quality of life differed between heart failure pa
tients managed with captopril plus diuretics and those with digoxin plus di
uretics. A total of 345 heart failure patients in New York Heart Associatio
n functional classes 2 and 3 without atrial fibrillation, dyspnea of bronch
opulmonary origin, or hypertension not controlled with diuretics was random
ized for digoxin (n = 175) or captopril (n = 170) treatment and followed up
for a median of 4.5 years. Socioeconomic, demographic, electrocardiographi
c, echocardiographic, spirometric, and chest radiograph data were obtained
at the initial examination. In a random sample of half the patients, ergome
tric, echocardiographic, and Holter records were obtained at entry and at 3
and 18 months. Patients were followed up for greater than or equal to 3 ye
ars. The end points were mortality, hospitalization for cardiac events, det
erioration in quality of life, worsening of functional class, and need for
digoxin or captopril in the captopril and digoxin groups, respectively. The
trial had to be terminated prematurely owing to the difficulty in finding
candidates free of angiotensin-converting enzyme (ACE)-inhibitor treatment.
Baseline patient characteristics were similar in both groups. From the cli
nical point of view, only the 48-month mortality was relevantly lower (20.9
vs. 31.9%, respectively) among patients treated with captopril than that i
n those receiving digoxin (log rank test, p = 0.07). No statistically or cl
inically relevant differences were found in other end points or adverse eff
ects. The results suggest but do not confirm the hypothesis that captopril
treatment in mild to moderate heart failure might provide better long-term
survival than digoxin.